MX2012000434A - Metodo de sanacion de herida y modulacion de cicatriz. - Google Patents

Metodo de sanacion de herida y modulacion de cicatriz.

Info

Publication number
MX2012000434A
MX2012000434A MX2012000434A MX2012000434A MX2012000434A MX 2012000434 A MX2012000434 A MX 2012000434A MX 2012000434 A MX2012000434 A MX 2012000434A MX 2012000434 A MX2012000434 A MX 2012000434A MX 2012000434 A MX2012000434 A MX 2012000434A
Authority
MX
Mexico
Prior art keywords
wound healing
scar
modulation
corticosteroids
administration
Prior art date
Application number
MX2012000434A
Other languages
English (en)
Spanish (es)
Inventor
Brian C Keller
Original Assignee
Crescendo Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crescendo Therapeutics Llc filed Critical Crescendo Therapeutics Llc
Publication of MX2012000434A publication Critical patent/MX2012000434A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2012000434A 2009-07-09 2010-07-09 Metodo de sanacion de herida y modulacion de cicatriz. MX2012000434A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22440809P 2009-07-09 2009-07-09
US22621609P 2009-07-16 2009-07-16
PCT/US2010/041576 WO2011006100A1 (en) 2009-07-09 2010-07-09 Method of wound healing and scar modulation

Publications (1)

Publication Number Publication Date
MX2012000434A true MX2012000434A (es) 2012-04-11

Family

ID=43427950

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000434A MX2012000434A (es) 2009-07-09 2010-07-09 Metodo de sanacion de herida y modulacion de cicatriz.

Country Status (10)

Country Link
US (1) US20110009374A1 (https=)
EP (1) EP2451280A4 (https=)
JP (1) JP2012532889A (https=)
CN (1) CN102480969A (https=)
AR (1) AR077410A1 (https=)
AU (1) AU2010271205A1 (https=)
BR (1) BR112012001098A2 (https=)
CA (1) CA2767661A1 (https=)
MX (1) MX2012000434A (https=)
WO (1) WO2011006100A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100322875A1 (en) 2009-06-18 2010-12-23 Advanced Bio-Technologies, Inc. Silicone scar treatment preparation
US8623040B2 (en) 2009-07-01 2014-01-07 Alcon Research, Ltd. Phacoemulsification hook tip
WO2012012390A1 (en) 2010-07-19 2012-01-26 Marvphyt Development Llc Botanical composition and methods of manufacture and use
US10258505B2 (en) 2010-09-17 2019-04-16 Alcon Research, Ltd. Balanced phacoemulsification tip
ITMI20111050A1 (it) * 2011-06-10 2012-12-11 Sevecom Spa Uso di emulsionanti in associazione con oleine vegetali in un alimento per animali.
ES2622849T3 (es) 2011-06-24 2017-07-07 Merz Pharma Gmbh & Co. Kgaa Composición que comprende un extracto de cebolla y liposomas
US9364510B2 (en) 2011-07-19 2016-06-14 Marvphyt Development Llc Botanical composition and methods of manufacture and use
EP4234545A3 (en) 2011-07-29 2023-09-06 Karyopharm Therapeutics Inc. Hydrazide containing nuclear transport modulators and uses thereof
MX369385B (es) * 2011-09-13 2019-11-07 Univ Brigham Young Productos para cicatrizar heridas tisulares.
US9474685B2 (en) 2011-09-28 2016-10-25 Sure-Shot Medical Device Inc. Apparatus for localized dermatological treatment
GB201120724D0 (en) * 2011-12-01 2012-01-11 Gauthier Rene System and method for alleviating the appearance of scars and/or scar tissue
FR2985064B1 (fr) * 2011-12-23 2016-02-26 Oreal Procede pour delivrer un conseil cosmetique
EP2841106A1 (en) * 2012-04-27 2015-03-04 Dow Corning Corporation Topical formulation compositions containing silicone based excipients to deliver actives to a substrate
WO2013170068A2 (en) 2012-05-09 2013-11-14 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US11458199B2 (en) * 2012-08-21 2022-10-04 Opko Pharmaceuticals, Llc Liposome formulations
US9808654B2 (en) * 2013-02-11 2017-11-07 Jan Marini Skin Research Post procedure skin care gel and methods of use thereof
EP2968278B8 (en) * 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
CN105122261B (zh) * 2013-04-23 2020-04-24 惠普发展公司，有限责任合伙企业 从遭到破坏的系统启动代码中恢复的方法以及计算装置
ME03421B (me) 2013-06-21 2020-01-20 Karyopharm Therapeutics Inc 1,2,4-triazoli kao modulatori nuklearnog transporta i njihova upotreba
US11432990B2 (en) 2013-08-30 2022-09-06 ISOS Solutions, LLC Textured apparatus with therapeutic material incorporated therein and methods of manufacturing same
US9226890B1 (en) 2013-12-10 2016-01-05 Englewood Lab, Llc Polysilicone base for scar treatment
EP3087495A4 (en) * 2013-12-23 2017-08-23 Intel Corporation Integrated component interconnect
WO2015189712A2 (en) * 2014-06-09 2015-12-17 Klox Technologies Inc. Silicone-based biophotonic compositions and uses thereof
BR112017000878B1 (pt) 2014-07-21 2022-05-10 Sevecom S.P.A. Mistura sólida, seu uso, e alimento para animal
KR102608259B1 (ko) 2014-08-15 2023-11-29 카리오팜 쎄라퓨틱스, 인코포레이티드 셀리넥소의 다형태
EP3397634A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
EP3548035A4 (en) * 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
JP2020514323A (ja) 2017-02-06 2020-05-21 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物と方法
CN113453670A (zh) * 2018-09-28 2021-09-28 乔·斯图丁 类固醇和大分子的透孔递送
KR102921276B1 (ko) 2018-11-21 2026-02-03 케이스 웨스턴 리저브 유니버시티 단쇄 데히드로게나아제 활성을 조절하는 조성물 및 방법
US20200397720A1 (en) * 2019-06-23 2020-12-24 Charles Huntington Gallina Method and formulation for treatment of wounds by new tissue regeneration with reduced trauma and scar tissue formation
CN110368498A (zh) * 2019-08-26 2019-10-25 瑞希(重庆)生物科技有限公司 一种促进伤口愈合的制剂及其制备方法
IL319751A (en) * 2022-07-27 2025-05-01 Bio Medical Sciences Inc Method for improving results of dermal tattoos and tattoo removal procedures

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337076B1 (en) * 1999-11-17 2002-01-08 Sg Licensing Corporation Method and composition for the treatment of scars
KR100362924B1 (ko) * 2000-01-11 2002-11-30 주식회사 동구약품 외피용약제 조성물
AU2001256347A1 (en) * 2000-05-23 2001-12-03 Unilever Plc Deodorant and/or antiperspirant compositions
GB0018466D0 (en) * 2000-07-27 2000-09-13 Strakan Pharm Ltd Keloid Treatment
US6610322B1 (en) * 2000-12-20 2003-08-26 Brian Charles Keller Self forming, thermodynamically stable liposomes and their applications
US6998421B2 (en) * 2001-06-07 2006-02-14 Biozone Laboratories, Inc. Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase - 2
US6495596B1 (en) * 2001-03-23 2002-12-17 Biozibe Laboratories, Inc. Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase-2
JP4450545B2 (ja) * 2001-07-05 2010-04-14 ロート製薬株式会社 エアゾール製剤
JP4549006B2 (ja) * 2002-05-07 2010-09-22 ロート製薬株式会社 ゲル軟膏
GB0216427D0 (en) * 2002-07-16 2002-08-21 Advanced Biotechnologies Inter Wound dressing
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20050014729A1 (en) * 2003-07-16 2005-01-20 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
AU2005253735A1 (en) * 2004-06-17 2005-12-29 Galderma S.A. Composition for the treatment of psoriasis comprising a silicone agent, a corticosteroid and vitamin D or a derivative thereof
MX2007015672A (es) * 2005-06-10 2008-02-20 Galderma Sa Liberacion controlada de un farmaco a traves de la piel sobre la base de una composicion topica que comprende el farmaco, una silicona formadora de pelicula y al menos un solvente volatil.
MX2009009557A (es) * 2007-03-08 2010-08-10 Crescendo Therapeutics Llc Formulaciones de aposito para prevenir o reducir la cicatrizacion.
US20080317830A1 (en) * 2007-06-25 2008-12-25 Liolabs Llc Compositions and Methods for the Treatment of Wounds and Scar Tissue
DE102009030931A1 (de) * 2009-06-24 2010-12-30 Eberhard-Karls-Universität Tübingen Universitätsklinikum Chirurgisches Wundverschlusselement

Also Published As

Publication number Publication date
AU2010271205A1 (en) 2012-02-09
JP2012532889A (ja) 2012-12-20
CN102480969A (zh) 2012-05-30
CA2767661A1 (en) 2011-01-13
EP2451280A1 (en) 2012-05-16
AR077410A1 (es) 2011-08-24
EP2451280A4 (en) 2012-12-26
BR112012001098A2 (pt) 2015-09-01
WO2011006100A1 (en) 2011-01-13
US20110009374A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
MX2012000434A (es) Metodo de sanacion de herida y modulacion de cicatriz.
MY163031A (en) Method of treating obesity using antioxidant inflammation modulators
PH12017500864A1 (en) Anti-notch1 antibodies
IN2012DN03883A (https=)
MX2011007930A (es) Conjugados de insulina cristalina.
CA2871471C (en) Dna-pk inhibitors
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
IN2012DN02081A (https=)
WO2012125544A3 (en) Necroptosis inhibitors and methods of use therefor
EP3715457A3 (en) Modulation of prekallikrein (pkk) expression
UA105487C2 (uk) Заміщені дигідропіразолони як інгібітори hif-проліл-4-гідроксилази
ZA201304940B (en) Granzyme b inhibitor compositions, methods and uses for promoting wound healing
UA118670C2 (uk) Способи та композиції для загоєння ран
NZ607149A (en) Galacto-oligosaccharide-containing composition and a method of producing it
MX357166B (es) Anticuerpos que se unen a notum pectinacetilesterasa.
MX2011009277A (es) Composicion de leucocito activada.
MX339361B (es) Derivados de alternano.
IN2014DN03010A (https=)
MX2013002539A (es) Sobrenadante condicionado por leucocitos activados y usos para la cicatrizacion de heridas.
WO2011136513A3 (ko) 디히드록시벤조산 유도체를 포함하는 골이식용 또는 골충진용 조성물
WO2012082942A3 (en) Neuropeptide analogs, compositions, and methods for treating pain
WO2011116351A3 (en) Methods and compositions for the treatment of cancer
WO2011044587A3 (en) Cytoprotective or therapeutic plant composition
MX2011007384A (es) Terapias de combinacion para trastornos neoplásticos.
WO2015050686A3 (en) Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: ABBVIE INC.

FA Abandonment or withdrawal